The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.
Jean-Luc Van Laethem
No relevant relationships to disclose
Volker Heinemann
No relevant relationships to disclose
Uwe Marc Martens
No relevant relationships to disclose
Jacek Jassem
No relevant relationships to disclose
Patrick Michl
No relevant relationships to disclose
Marc Peeters
No relevant relationships to disclose
Colin D. Weekes
Consultant or Advisory Role - Bayer
Raphael Maréchal
No relevant relationships to disclose
Jens Stieler
No relevant relationships to disclose
Marius Giurescu
Employment or Leadership Position - Bayer
Prabhu Rajagopalan
Employment or Leadership Position - Bayer
Vittorio Luigi Garosi
Employment or Leadership Position - Bayer
Hanno Riess
No relevant relationships to disclose